Skip to main content
Premium Trial:

Request an Annual Quote

Tim Harkness, Deborah Smeltzer, Phillip Vorwald, Kyle Kolaja, Robert Herbold, Frank Baldino, Joseph Papa

Molecular Devices gave chief financial officer, Tim Harkness, a 16-percent raise, the company said in a December SEC filing. Harkness, who is also senior vice president and has been with the company since 1998, will receive an annual salary of $275,000 and a performance bonus of up to 60 percent of that based on undisclosed performance goals. Harkness received a salary of $237,499 in 2003, and a bonus of $142,500. The new agreement includes new severance benefits for Harkness that include: a one-year consultancy with 12 monthly cash payments equivalent to his salary at the time of separation, and 100 percent of his bonus; and the vesting of any outstanding stock options. If the company is bought, Harkness can collect 18 months of salary and 1.5 times the full bonus; and have his options vest immediately.

In 2003, Harkness received 32,500 options at a price of $15.85 a share, representing 6 percent of the options the company granted. Harkness joined Molecular Devices from physician practice management firm Vivra Specialty Partners, where he was vice president of business development. He previously worked with Montgomery Securities, and with Arthur Andersen.

Deborah Smeltzer joins Dynavax Technologies of Berkeley, Calif., as vice president of operations and chief financial officer. Smeltzer previously was vice president and general manager of Applied Biosystems, where she oversaw the company's genomics applications business. Previously, she worked for Genset of Paris as CFO.

Phillip Vorwald joins Guava Technologies as vice president of worldwide sales, the company said this week. Vorwald previously was managing director of Delphi Medical Systems, a unit he developed. Previously, he was vice president for business operations for most of the world outside North America for Becton Dickinson Biosciences. Vorwald will develop new markets for Guava’s cell analysis products, the company said in a statement.

Kyle Kolaja joined Iconix Pharmaceuticals of Mountain View, Calif., as vice president of chemogenomics and toxicology, the company said. He will be responsible for in vivo and in vitro chemogenomics studies and serves as the corporate toxicologist, providing scientific input into all external investigative collaborations. Kolaja previously was with Pharmacia.

Robert Herbold joins the board of directors of Icos of Bothell, Wash., effective March 16, the company said. Herbold, managing director of Herbold Group, previously was executive vice president and chief operating officer of Microsoft, and before that senior vice president of advertising and information services for Proctor & Gamble. He also serves on the board of directors of Agilent Technologies, Weyerhaeuser, First Mutual Bank, and Cintas.

Frank Baldino, chairman and CEO of Cephalon, has joined the board of directors of the Pennsylvania Bio, the group said recently. Baldino served as senior research biologist in the medical products department at E I DuPont de Nemours, where he was responsible for developing research strategies for identifying novel neuropharmaceutical agents.

Joseph Papa joined Cardinal Health of Dublin, Ohio, as chairman and CEO for its pharmaceutical technologies and services business. Papa previously was president and COO of Watson Pharmaceuticals. He has previously served as an executive for DuPont Pharmaceuticals, Pharmacia, and Searle Pharmaceuticals.


The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.